·
Future Growth of oncology
drug market is expected to be led by countries such as India, China and others
·
The market leader, Roche is
expected to maintain focus on Emerging Markets and global brands to compete
with other players in the industry.
Ken Research announced its latest
publication on “Asia Oncology Drug Market Outlook to 2019 – Rise in Cancer incidences and Ageing
Population to Drive the Demand” which provides a
comprehensive analysis of the oncology drug market in Asia. The report covers
various aspects such as market size of Asia oncology market, segmentation on
the basis of type of modalities, treatment, global and local players, and type
of cancer. The report also covers India as well as China oncology drug market
in different aspects such as market size, segmentation on the basis of type of treatment,
cost of treatment and import and export of anti-cancer drugs in the market. The
report is useful for oncology drugs manufacturers, hospitals, government
association, retail chains and new players venturing in the market.
 |
| Asia Cancer Drugs Market |
The Asia oncology market has witnessed a growth in
recent years on account of rising demand for anti-cancer drugs fueled by
increase in healthcare expenditure, rising awareness and affordability. The surge in growth is majorly originated
from growth in Breast and Blood Cancer as a segment of cancer market. The
growth is Asia oncology drug market is fueled by growth in markets of India,
China and Japan. The growth in these countries has been largely led by the
domestic factors such as supportive government policies, increasing demand and
entry of new player in oncology drug market. The Asia Oncology drug market is
comprised of large companies such as Roche which posses a large product
portfolio of oncology drugs. The Asia oncology drug market revenues have grown
at a CAGR of 4.3% from 2009-2014.
According to the research report, the Asia
oncology drug market will grow at a considerable CAGR and will exceed over USD 20
billion by 2017 due to the increasing number of players, rising incidence of
cancer and increasing demand for the oncology drugs
“Boom in ageing population in China and Japan,
rising intake of health insurance and an increase in the out of pocket
healthcare expenditure will result in increased revenue of oncology drug market
in the Asia, volatility in global product prices, enhancing competition and
development of generic drugs are few of the major challenges which will affect
the growth of this industry in the future”, according to the Research Analyst,
Ken Research.
Key Topics Covered in the Report:
Oncology Drugs
-
Market Size by Revenue
-
Market Segmentation by
o Therapeutic Modalities
o Generic and Patented Drugs
o Local Players and Global Players
-
Trends and Development
-
SWOT
-
Export and Import
-
Competition and Market Share
-
Growth Drivers
-
Future Outlook
-
Macro Economic Parameters
-
Key Products Mentioned in the Report
-
Generic Cancer Drugs
-
Patented Cancer Drugs
-
Chemotherapy
-
Targeted Therapy
-
Hormone Therapy
-
Immuno Therapy
-
Avsatin
-
Herceptin
-
Xalkori
-
Sutent
-
Gleevec
-
Arimidex
-
Revlimid
Companies Covered in the Report
Global Players
-
Roche
-
Pfizer
-
Novartis
-
Celgene
-
GlaxoSmithKline
-
AstraZeneca
-
Eli Lily
Domestic Players-India
-
Cipla Ltd
-
Sun Pharma Pharmaceuticals
Ltd
-
Dr Reddy Laboratories Ltd
-
NATCO Pharmaceuticals Ltd
-
Biocon Ltd.
Domestic Players-China
-
Jiang Su Heng Rui Medicine Co.
Ltd
-
Qilu Pharmaceuticals Co. Ltd
-
Jiangsu Hansoh Pharmaceutical
Co. Ltd
-
Luye Pharma Group Ltd
-
Livzon Pharmaceutical Group
Related Reports:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
No comments:
Post a Comment